HK Stock Market Move | ZHAOKE OPHTH-B(06622) rose more than 5% in midday trading. The drug Cristabetin, which is used to treat glaucoma, has been approved for market launch.

09:52 20/09/2024

Tricorono Eye Clinic-B (06622) rose more than 5% intraday, and as of the time of writing, rose by 3.7% to 1.4 Hong Kong dollars, with a trading volume of 496,500 Hong Kong dollars.

, ZHAOKE OPHTH-B (06622) rose more than 5% during trading hours, and as of the time of writing, it has increased by 3.7% to 1.4 Hong Kong dollars, with a turnover of 496,500 Hong Kong dollars. On the news front, Zhaoke Ophthalmology announced this morning that its anti-glaucoma drug Bymicrontal prostaglandin eye drops (Crystalbet Clear) developed and produced by the company has been approved for listing by the National Medical Products Administration. It is reported that Bymicrontal prostaglandin eye drops (Crystalbet Clear) is the first single dosage prostaglandin eye drops in China without preservatives, used to reduce eye pressure in patients with angle-closure glaucoma and high eye pressure.

Shareholder Weng Zhanguo of Shanxi C&Y Pharmaceutical Group (stock code: 300254.SZ) plans to reduce his shareholding by no more than 3%.

Shanghai Petrochemical's (00338) gasoline sales revenue in the first three quarters was 19.743 billion yuan.

Vice President Fu Lihua of Ganfeng Lithium Group (01772) plans to reduce his shareholding in the company by no more than 40,000 shares.

Shareholder Weng Zhanguo of Shanxi C&Y Pharmaceutical Group (stock code: 300254.SZ) plans to reduce his shareholding by no more than 3%.

Shanghai Petrochemical's (00338) gasoline sales revenue in the first three quarters was 19.743 billion yuan.

Vice President Fu Lihua of Ganfeng Lithium Group (01772) plans to reduce his shareholding in the company by no more than 40,000 shares.